Galmed Pharmaceuticals Ltd. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Ramat Gan, IL. Its latest filed balance sheet (2025-12-31) shows total assets of $19 million (its filed statements).
Pre-revenue companyPharmaceutical PreparationsRamat Gan, ILfilings since 20135 of 9 filed, 4 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.1 out of ten, 5 of 9 metrics filed and 4 estimated: past 4.4 out of ten, present 5.6 out of ten, future 2.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 4.7 out of ten. 5 filed years; profitable in 1 of 5. 47th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 1.4 out of ten. Share count grew 213.6% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases. 14th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 6.2 out of ten. ROE 44%: 44¢ of profit per shareholder dollar. Leverage 15%: owes 15¢ per asset dollar. 62nd percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.2 out of ten. CrossAssetData estimate 5.2/10, confidence 20 of 100 (family median). 50th percentile among 314 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 371 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 4.3 out of ten. CrossAssetData estimate 4.3/10, confidence 35 of 100 (one part). 43rd percentile among 479 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Growth drivers (future): 2.5 out of ten. bottom 25% of 307 in its family for growth drivers. 25th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 0.3 out of ten. CrossAssetData estimate 0.3/10, confidence 35 of 100 (one part). 2nd percentile among 285 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 20-F filed 2026-03-31 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-09-09. Filings on record since 2013. Read from EDGAR 2026-10-12.
Who runs it
Baharaff, Allen (Chief Executive Officer); Cohen, Doron Leib (Chief Financial Officer); Nehemya, Guy (Chief Operating Officer); Nissimov, Brueck Liat (Chief Scientific Officer); Stenzler, Yohai (Chief Accounting Officer); Brosgart, Carol L (director); Nir, Shmuel (director); Poshinski, Amir (director); Sidransky, David (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.